Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.

Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
复制标题

DOI:
10.1002/cncr.31050
复制
发表时间:
2018-01-15
期刊:
影响因子:
6.2
通讯作者:
Shih YT
Shih YT
中科院分区:
医学1区
文献类型:
--
作者:
Shen C;Zhao B;Liu L;Shih YT

文献摘要

参考文献

被引文献

相似文献

Tyrosine kinase inhibitors (TKIs) improve survival of chronic myeloid leukemia (CML) patients dramatically; however, non-adherence to TKI therapy may lead to resistance to the therapy. They are very expensive and covered under Part D insurance for Medicare patients. The impact of low-income subsidy status and cost-sharing on adherence was not well studied in the literature among this group. Surveillance, Epidemiology, and End Results (SEER) registry data linked with Medicare Part D data from years 2007–2012 was used in this study. We identified 836 CML patients with Medicare Part D insurance coverage who were new TKI users. Treatment non-adherence was defined as a binary variable indicating proportion of days covered (PDC) lower than 80% during the 180-day period after TKI therapy initiation. Logistic regression was used to examine the relationship between out of pocket (OOP) cost per 30-day drug supply, Part D plan characteristics and treatment adherence while controlling for other patient characteristics. Overall 244 (29%) of the 836 CML patients were non-adherent to targeted oral therapy during the 180 days after they began taking the TKIs. The multivariable logistic regression showed that patients with heavily subsidized (OR=6.7, 95% CI: 2.8~15.9) and moderately subsidized (OR=3.0, 95% CI: 1.4~6.5) Part D plans were much more likely to have non-adherence than patients without subsidy. This population-based study found a significantly higher rate of non-adherence among heavily subsidized patients with substantially lower OOP costs, which suggests that future research is needed to help lower the non-adherence rate among these patients.
DOI: 10.1053/j.gastro.2013.11.051
发表时间: 2014-02
期刊: Gastroenterology
影响因子: 29.4
作者:
Alemán JO;Eusebi LH;Ricciardiello L;Patidar K;Sanyal AJ;Holt PR
通讯作者: Holt PR
DOI: 10.1007/s10120-012-0155-4
发表时间: 2013-04-01
期刊: GASTRIC CANCER
影响因子: 7.4
作者:
Lavy, Ron;Kapiev, Andronik;Keinan-Boker, Lital
通讯作者: Keinan-Boker, Lital
DOI: 10.1111/hel.12227
发表时间: 2015-12-01
期刊: HELICOBACTER
影响因子: 4.4
作者:
Muhsen, Khitam;Goren, Sophy;Cohen, Dani
通讯作者: Cohen, Dani
DOI: 10.1007/s10120-014-0429-0
发表时间: 2015-10-01
期刊: GASTRIC CANCER
影响因子: 7.4
作者:
Kim, Hee Jin;Kim, Nayoung;Lee, Dong Ho
通讯作者: Lee, Dong Ho
DOI: 10.1002/ijc.10149
发表时间: 2002-02-20
影响因子: 6.4
作者:
Inoue, M;Ito, LS;Tominaga, S
通讯作者: Tominaga, S